Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06954831 · ClinicalTrials.gov registry record · Phase 2
Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
A Phase 2 study of Breast Carcinoma and Anatomic Stage III Breast Cancer AJCC v8, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
- 7
- Study locations
NCT06954831 is a Phase 2 study of Breast Carcinoma and Anatomic Stage III Breast Cancer AJCC v8 that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 82 participants, below the 770-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (89% lower). The trial reports 7 study locations across 1 state.
The verdict
NCT06954831, a Phase 2 study of Breast Carcinoma and Anatomic Stage III Breast Cancer AJCC v8, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
- 7
- Study locations
Study Summary
This clinical trial tests how well ultra-hypofractionated (UF) whole breast irradiation (WBI) with lumpectomy cavity boost (CB) works in treating patients with stage I-III breast cancer. Breast conservation therapy (BCT) is the recommended treatment for patients with early stage breast cancer. BCT involves a lumpectomy followed by breast radiation. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Traditionally, WBI has been given once daily over 5-6 weeks and then those at high-risk for recurrence receive additional radiation (boost) to the lumpectomy cavity daily over 4-8 days. This has now been replaced by moderate hypofractionated radiation. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Although moderate hypofractionated radiation therapy reduces the length of treatment from 6-7 weeks to 3-4 weeks, the length of treatment still remains a barrier for many patients. UF-WBI with CB delivers radiation to the whole breast and the surgical cavity at the same time over 5 daily treatments. Giving UF-WBI with CB may prevent recurrence and prolong survival as well as improve the quality of life in patients with stage I-III breast cancer.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- PROCEDURE Cone-Beam Computed Tomography
- RADIATION Hypofractionated External Beam Radiation Therapy
- RADIATION Radiation Boost
- RADIATION Whole Breast Irradiation
Study Locations (7)
California
- City of Hope at Arcadia - Arcadia
- City of Hope Medical Center - Duarte
- City of Hope at Irvine Lennar - Irvine
- City of Hope Antelope Valley - Lancaster
- City of Hope South Pasadena - South Pasadena
- City of Hope at South Bay - Torrance
- City of Hope Upland - Upland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2025-08-28 |
| Est. Completion | 2028-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06954831
The ClinicalTrials.gov registry entry for NCT06954831 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 770-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (89% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Breast Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Questionnaire Administration is the first listed.
NCT06954831 reports 7 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06954831 about?
NCT06954831 is a clinical study titled "Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer". This clinical trial tests how well ultra-hypofractionated (UF) whole breast irradiation (WBI) with lumpectomy cavity boost (CB) works in treating patients with stage I-III breast cancer. Breast conservation therapy (BCT) is the recommended treatment for patients with early stage breast cancer. BCT i...
What is the current status of trial NCT06954831?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2025-08-28. Estimated completion is 2028-01-31.
What conditions does trial NCT06954831 study?
This clinical trial studies the following conditions: Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8.
What interventions are being tested in trial NCT06954831?
The interventions under investigation include: Questionnaire Administration (OTHER), Cone-Beam Computed Tomography (PROCEDURE), Hypofractionated External Beam Radiation Therapy (RADIATION), Radiation Boost (RADIATION), Whole Breast Irradiation (RADIATION).
Who is sponsoring clinical trial NCT06954831?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06954831 being conducted?
This trial has 7 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
RECRUITING · Phase 2
-
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
RECRUITING · Phase 2
-
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
RECRUITING · Phase 2
-
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
RECRUITING · Phase 2
-
Study of Aerobic Training for People Receiving Chemotherapy for Breast Cancer
RECRUITING · Phase 2
-
EMBRACE: Exercising Together
RECRUITING · Phase 2
Explore more on PlainTrial
Breast Carcinoma
All registered trials for this condition
Anatomic Stage III Breast Cancer AJCC v8
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.